Loading...

Ionis Pharmaceuticals

DB:ISI
Snowflake Description

Adequate balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ISI
DB
$10B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The last earnings update was 49 days ago. More info.


Add to Portfolio Compare Print
ISI Share Price and Events
7 Day Returns
-14.9%
DB:ISI
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
64.3%
DB:ISI
-10.6%
DE Biotechs
-6.2%
DE Market
ISI Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Ionis Pharmaceuticals (ISI) -14.9% -9.7% 26.1% 64.3% 65.1% -
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • ISI outperformed the Biotechs industry which returned -10.6% over the past year.
  • ISI outperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
ISI
Industry
5yr Volatility vs Market

ISI Value

 Is Ionis Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Ionis Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Ionis Pharmaceuticals.

DB:ISI Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 15 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.3%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:ISI
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (6.4%))
1.349
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.35
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.349 * 5.96%)
8.27%

Discounted Cash Flow Calculation for DB:ISI using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Ionis Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:ISI DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.27%)
2019 55.00 Analyst x3 50.80
2020 56.67 Analyst x3 48.34
2021 297.75 Analyst x4 234.61
2022 448.50 Analyst x4 326.41
2023 605.50 Analyst x4 407.02
2024 732.27 Est @ 20.94% 454.65
2025 840.09 Est @ 14.72% 481.76
2026 927.24 Est @ 10.37% 491.14
2027 995.22 Est @ 7.33% 486.89
2028 1,046.97 Est @ 5.2% 473.09
Present value of next 10 years cash flows $3,454.73
DB:ISI DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $1,046.97 × (1 + 0.23%) ÷ (8.27% – 0.23%)
$13,052.27
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $13,052.27 ÷ (1 + 8.27%)10
$5,897.92
DB:ISI Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $3,454.73 + $5,897.92
$9,352.64
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $9,352.64 / 138.40
$67.58
DB:ISI Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:ISI represents 0.86998x of NasdaqGS:IONS
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.86998x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 67.58 x 0.86998
€58.79
Value per share (EUR) From above. €58.79
Current discount Discount to share price of €63.50
= -1 x (€63.50 - €58.79) / €58.79
-8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Ionis Pharmaceuticals is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Ionis Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Ionis Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:ISI PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $2.09
NasdaqGS:IONS Share Price ** NasdaqGS (2019-04-18) in USD $72.99
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Ionis Pharmaceuticals.

DB:ISI PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:IONS Share Price ÷ EPS (both in USD)

= 72.99 ÷ 2.09

34.88x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ionis Pharmaceuticals is overvalued based on earnings compared to the Europe Biotechs industry average.
  • Ionis Pharmaceuticals is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Ionis Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:ISI PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 34.88x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 15 Analysts
18.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

DB:ISI PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 34.88x ÷ 18.7%

1.87x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ionis Pharmaceuticals is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Ionis Pharmaceuticals's assets?
Raw Data
DB:ISI PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $7.60
NasdaqGS:IONS Share Price * NasdaqGS (2019-04-18) in USD $72.99
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:ISI PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:IONS Share Price ÷ Book Value per Share (both in USD)

= 72.99 ÷ 7.60

9.61x

* Primary Listing of Ionis Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ionis Pharmaceuticals is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Ionis Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Ionis Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ISI Future Performance

 How is Ionis Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 15 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
18.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Ionis Pharmaceuticals expected to grow at an attractive rate?
  • Ionis Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Ionis Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Ionis Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:ISI Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:ISI Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 15 Analysts 18.7%
DB:ISI Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 15 Analysts 15.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:ISI Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 15 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:ISI Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,437 469 440 5
2022-12-31 1,272 363 307 7
2021-12-31 1,049 296 207 10
2020-12-31 968 186 72 15
2019-12-31 793 144 34 15
DB:ISI Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 600 603 277
2018-09-30 569 508 -50
2018-06-30 542 563 -35
2018-03-31 536 65 -1
2017-12-31 514 174 19
2017-09-30 507 127 42
2017-06-30 499 122 52
2017-03-31 426 86 -15
2016-12-31 373 -112 -60
2016-09-30 238 -123 -184
2016-06-30 176 -111 -227
2016-03-31 258 -12 -134

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Ionis Pharmaceuticals's earnings are expected to grow by 18.7% yearly, however this is not considered high growth (20% yearly).
  • Ionis Pharmaceuticals's revenue is expected to grow by 15.8% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:ISI Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 15 Analyst Estimates (S&P Global) See Below

All data from Ionis Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:ISI Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 2.75 4.55 0.98 5.00
2022-12-31 2.05 4.87 0.18 7.00
2021-12-31 1.16 3.45 -0.71 10.00
2020-12-31 0.55 1.96 -0.61 14.00
2019-12-31 0.03 1.00 -1.40 16.00
DB:ISI Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 2.09
2018-09-30 -0.38
2018-06-30 -0.28
2018-03-31 -0.01
2017-12-31 0.15
2017-09-30 0.34
2017-06-30 0.42
2017-03-31 -0.12
2016-12-31 -0.50
2016-09-30 -1.52
2016-06-30 -1.89
2016-03-31 -1.12

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Ionis Pharmaceuticals is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Ionis Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Ionis Pharmaceuticals has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ISI Past Performance

  How has Ionis Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Ionis Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Ionis Pharmaceuticals has delivered over 20% year on year earnings growth in the past 5 years.
  • Ionis Pharmaceuticals's 1-year earnings growth exceeds its 5-year average (1373.3% vs 37.4%)
  • Ionis Pharmaceuticals's earnings growth has exceeded the Europe Biotechs industry average in the past year (1373.3% vs 18.2%).
Earnings and Revenue History
Ionis Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Ionis Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:ISI Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 599.67 276.87 244.62
2018-09-30 568.84 -49.82 224.27
2018-06-30 541.76 -34.75 182.35
2018-03-31 536.29 -0.72 138.46
2017-12-31 514.18 18.79 108.49
2017-09-30 506.74 42.19 80.82
2017-06-30 499.35 51.51 64.22
2017-03-31 425.55 -14.68 51.73
2016-12-31 372.78 -60.40 48.62
2016-09-30 237.84 -183.85 43.76
2016-06-30 176.04 -226.98 42.32
2016-03-31 257.99 -134.48 40.27
2015-12-31 283.70 -88.28 37.17
2015-09-30 316.99 14.21 30.82
2015-06-30 311.94 23.31 26.54
2015-03-31 248.58 -24.42 23.23
2014-12-31 214.16 -38.98 20.14
2014-09-30 171.55 -94.31 17.99
2014-06-30 151.07 -92.21 16.95
2014-03-31 132.09 -90.25 15.88
2013-12-31 147.29 -60.64 14.92
2013-09-30 124.91 -39.01 13.48
2013-06-30 112.93 -52.07 9.74
2013-03-31 122.17 -43.16 11.23
2012-12-31 102.05 -65.48 12.52
2012-09-30 114.58 -82.88 15.96
2012-06-30 123.69 -72.12 22.29

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Ionis Pharmaceuticals has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Ionis Pharmaceuticals used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • It is difficult to establish if Ionis Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Ionis Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Ionis Pharmaceuticals has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ISI Health

 How is Ionis Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Ionis Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Ionis Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Ionis Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Ionis Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Ionis Pharmaceuticals Company Filings, last reported 3 months ago.

DB:ISI Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 1,187.16 646.72 2,086.63
2018-09-30 840.14 638.62 1,958.99
2018-06-30 817.44 625.84 1,980.45
2018-03-31 387.10 614.42 1,035.30
2017-12-31 365.28 607.48 1,022.72
2017-09-30 397.67 597.65 1,010.81
2017-06-30 215.57 604.13 855.71
2017-03-31 201.81 595.91 860.28
2016-12-31 99.57 589.11 665.22
2016-09-30 139.64 495.27 697.23
2016-06-30 111.21 484.99 672.31
2016-03-31 158.16 478.90 723.51
2015-12-31 200.79 472.96 803.98
2015-09-30 245.41 472.07 830.79
2015-06-30 300.32 466.90 815.54
2015-03-31 275.85 462.27 788.50
2014-12-31 257.78 457.78 810.71
2014-09-30 344.77 234.76 640.43
2014-06-30 366.86 233.92 649.37
2014-03-31 374.10 233.23 697.78
2013-12-31 378.39 232.57 710.13
2013-09-30 401.45 230.84 737.73
2013-06-30 401.08 230.24 654.38
2013-03-31 201.09 227.27 419.39
2012-12-31 182.77 226.82 412.94
2012-09-30 170.28 226.46 346.76
2012-06-30 154.31 231.05 338.63
  • Ionis Pharmaceuticals's level of debt (54.5%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (61.5% vs 54.5% today).
  • Debt is well covered by operating cash flow (93.2%, greater than 20% of total debt).
  • Unable to confirm if the interest payments on Ionis Pharmaceuticals's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Ionis Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Ionis Pharmaceuticals has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ISI Dividends

 What is Ionis Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Ionis Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Ionis Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Ionis Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Ionis Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:ISI Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 15 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:ISI Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Ionis Pharmaceuticals has not reported any payouts.
  • Unable to verify if Ionis Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Ionis Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Ionis Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Ionis Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Ionis Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Ionis Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Ionis Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ISI Management

 What is the CEO of Ionis Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Stan Crooke
COMPENSATION $7,314,652
AGE 73
TENURE AS CEO 30.3 years
CEO Bio

Dr. Stanley T. Crooke, M.D., Ph.D., also known as Stan, has been the Chairman of Ionis Pharmaceuticals, Inc. since February 1991 and has been its Chief Executive Officer since January 1989. Dr. Crooke serves as the President of Ionis Pharmaceuticals, Inc. He serves as an Editor-in-Chief of Current Opinion in Anticancer Drugs and Section Editor for Biologicals and Immunologicals for Expert Opinion on Investigational Drugs. He has been an Executive Director at Isis Pharmaceuticals, Inc. since January 1989. Dr. Crooke founded Ionis Pharmaceuticals, Inc. in 1989 and served as its President from January 1989 to May 1994. He served as the President of Research and Development for SmithKline & French Laboratories at SmithKline Beckman Corporation from 1980 to January 1989. He coordinated the research and development activities of SKB including its instruments, diagnostics, animal health and clinical laboratory businesses. He is the named inventor on some of the key patents in the field of RNA-targeted therapeutics and has over 30 years of drug discovery and development experience. He has dedicated over 26 years to discovering and developing Ionis' antisense technology platform. He helped establish the anticancer drug discovery and development program at Bristol Myers, which succeeded in bringing to market a significant number of drugs. He served at Valentis Inc. During his career, he supervised the development of 19 drugs on the market and others in development. Dr. Crooke served as the Chairman of the Board of GeneMedicine, Inc. since March 1996. He served as the Chairman of Akcea Therapeutics, Inc. and was its Director since January 2015 till October 8, 2018. He serves as a Director of Megabios Corp. and EPIX Medical, Inc. Dr. Crooke served as a Director of Regulus Therapeutics Inc. from January 2009 to November 5, 2012. He serves as a Director of Symphony GenIsis Inc. and The Annapolis Center for Science-Based Public Policy. Previously, Dr. Crooke served as a Director of Regulus Therapeutics LLC. since November 2007. He served as a Director of Applied Molecular Evolution, Inc. He served as a Non Executive Director of Axon Instruments Inc. He served as a Non Executive Director of Antisense Therapeutics Ltd. from October 31, 2001 to July 31, 2006. He served as a Director of EPIX Pharmaceuticals, Inc. from 1996 to June 22, 2005 and Iteration Energy Ltd. from July 15, 1999 to March 19, 2002. He served as a Director of IDUN Pharmaceuticals, Inc. He served as a Director of GeneMedicine, Inc. since March 1992 and SIBIA Neurosciences, Inc. since 1992. Dr. Crooke also served academic positions. Dr. Crooke is a Member of the San Diego State University BioScience Center Scientific Advisory Board, the Current Drugs Advisory Board and the Editorial Board of Gene Therapy and Molecular Biology. Dr. Crooke serves as an Adjunct Professor of Pharmacology at the University of California, San Diego and San Diego State University. He served for a number of years as Adjunct Professor of Pharmacology at Baylor College of Medicine. He serves on the Board of Northern Arizona University Arts and Sciences Advisory Council, Flagstaff, Arizona. He has authored over 415 publications and edited 19 books. Dr. Crooke is active in molecular and cellular biology and pharmacology of antisense oligonucleotides. In 2006, he was named in Nature Biotechnology as one of biotechnology's influential individuals. Dr. Crooke received his Ph.D. in Pharmacology and M.D. from Baylor College of Medicine, Houston, Texas and B.S. in Pharmacy from Butler University, Indianapolis, Indiana.

CEO Compensation
  • Stan's compensation has been consistent with company performance over the past year.
  • Stan's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Ionis Pharmaceuticals management team in years:

6.5
Average Tenure
60
Average Age
  • The average tenure for the Ionis Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Stan Crooke

TITLE
Founder
COMPENSATION
$7M
AGE
73
TENURE
30.3 yrs

Brett Monia

TITLE
Founder
COMPENSATION
$2M
AGE
57

Elizabeth Hougen

TITLE
Senior VP of Finance & CFO
COMPENSATION
$2M
AGE
56
TENURE
6.3 yrs

Richard Geary

TITLE
Senior Vice President of Development
COMPENSATION
$2M
AGE
60
TENURE
10.7 yrs

B. Parshall

TITLE
Senior Strategic Advisor & Director
COMPENSATION
$5M
AGE
64
TENURE
1.3 yrs

D. Walke

TITLE
Vice President of Investor Relations
TENURE
6.8 yrs

Patrick O'Neil

TITLE
Senior VP of Legal
COMPENSATION
$2M
AGE
44
TENURE
6.3 yrs

Roslyn Patterson

TITLE
Vice President of Corporate Communications

C. Bennett

TITLE
Senior Vice President of Antisense Research
COMPENSATION
$959K
AGE
61
TENURE
13.3 yrs

Sanjay Bhanot

TITLE
Chief Medical Officer & CardioMetabolic Franchise Leader
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Ionis Pharmaceuticals board of directors in years:

15.1
Average Tenure
66
Average Age
  • The average tenure for the Ionis Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Stan Crooke

TITLE
Founder
COMPENSATION
$7M
AGE
73
TENURE
28.2 yrs

Brett Monia

TITLE
Founder
COMPENSATION
$2M
AGE
57
TENURE
0.1 yrs

Joseph Wender

TITLE
Director
COMPENSATION
$731K
AGE
73
TENURE
25.3 yrs

Spencer Berthelsen

TITLE
Director
COMPENSATION
$732K
AGE
66
TENURE
16.9 yrs

Skip Klein

TITLE
Director
COMPENSATION
$704K
AGE
57
TENURE
13.3 yrs

B. Parshall

TITLE
Senior Strategic Advisor & Director
COMPENSATION
$5M
AGE
64
TENURE
18.6 yrs

Frederick Muto

TITLE
Director
COMPENSATION
$697K
AGE
65
TENURE
18.1 yrs

Breaux Castleman

TITLE
Director
COMPENSATION
$704K
AGE
78
TENURE
5.8 yrs

Joseph Loscalzo

TITLE
Director
COMPENSATION
$712K
AGE
67
TENURE
5.2 yrs

Peter Reikes

TITLE
Director
TENURE
0.6 yrs
Who owns this company?
Recent Insider Trading
  • Ionis Pharmaceuticals insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
05. Apr 19 Sell Patrick O'Neil Individual 04. Apr 19 04. Apr 19 -3,000 €75.08 €-223,011
20. Mar 19 Sell Joseph Wender Individual 19. Mar 19 19. Mar 19 -10,000 €70.15 €-701,503
X
Management checks
We assess Ionis Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Ionis Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ISI News

Simply Wall St News

ISI Company Info

Description

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is involved in developing neurology products that include IONIS-HTTRx for Huntington’s diseases; and IONIS-SOD1Rx and IONIS-C9Rx for amyotrophic lateral sclerosis and IONIS-MAPTRx for Alzheimer's diseases. The company is also developing severe and rare disease products, such as WAYLIVRA, a treatment for familial chylomicronemia syndrome; WAYLIVRA, a treatment for familial partial lipodystrophy; AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; and IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity, IONIS-PKKRx/IONIS-PKK-LRx for hereditary angioedema, and IONIS-ENAC-2.5Rx for cystic fibrosis. In addition, its cardio metabolic and renal drugs include AKCEA-ANGPTL3-LRx for cardio metabolic disorders, IONIS-FXIRx for clotting disorders, AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases, and IONIS-DGAT2Rx for nonalcoholic steatohepatitis; IONIS-AGT-LRX for the treatment of resistant hyper tension; and IONIS-FXI-LRx for clotting disorders and IONIS-AZ4-2.5-LRx for cardiovascular diseases. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; and IONIS-HBVRx and IONIS-HBV-LRx for hepatitis b virus infection, and IONIS-FB-LRx for compliment meditated disease, and IONIS-JBI1-2.5Rx for gastrointestinal autoimmune diseases. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Details
Name: Ionis Pharmaceuticals, Inc.
ISI
Exchange: DB
Founded: 1989
$8,982,389,015
138,397,754
Website: http://www.ionispharma.com
Address: Ionis Pharmaceuticals, Inc.
2855 Gazelle Court,
Carlsbad,
California, 92010,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS IONS Common Stock Nasdaq Global Select US USD 17. May 1991
DB ISI Common Stock Deutsche Boerse AG DE EUR 17. May 1991
LSE 0JDI Common Stock London Stock Exchange GB USD 17. May 1991
SWX IONS Common Stock SIX Swiss Exchange CH CHF 17. May 1991
Number of employees
Current staff
Staff numbers
737
Ionis Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 20:34
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/18
Last earnings filing: 2019/03/01
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.